Articles

Resistance to PI3κδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Centro di Riferimento Oncologico di Aviano – CRO, Aviano
Centro di Riferimento Oncologico di Aviano – CRO, Aviano
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona
Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia
Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona
Oncology Institute of Southern Switzerland, Bellinzona
Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Faculty of Biomedical Sciences, USI, Bellinzona
Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia
Oncology Institute of Southern Switzerland, Bellinzona
Centro di Riferimento Oncologico di Aviano – CRO, Aviano
Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain; Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Bellinzona
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Bellinzona
Haematologica Early view Apr 28, 2022 https://doi.org/10.3324/haematol.2021.279957